Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
- beauty
- industrial
- pharma
Sodium phosphate, dibasic, heptahydrate
CAS 1803394-07-1
Concern score
Not assessed — no hazard data yet.
Why it's flagged
EPA CPDat observed this chemical in 15 composition records across product categories including Laboratory supplies, Personal care, Medical/dental.
Regulation
No restrictions found. Sodium phosphate, dibasic, heptahydrate appears in these published regulatory listings.
- commercial_presence
- consumer_product_presence
- cpdat_category:beauty|industrial
- currently_marketed_ndc
- definition_level:complete
- definition_type:primary
- inactive_ingredient_database
- ingredient_type:ingredient substance
USFDAinactive ingredient database45 entries — 16 administration routes
- Route: AURICULAR (OTIC); Dosage form: DROPS; Potency: 0.3 %w/wSource →
- Route: AURICULAR (OTIC); Dosage form: SOLUTION; Potency: 0.5 %w/wSource →
- Route: DENTAL; Dosage form: PASTE, DENTIFRICE; Potency: 0.56 %w/wSource →
- Route: INTRA-ARTICULAR; Dosage form: INJECTION; Maximum daily exposure: 3 mgSource →
- Route: INTRA-ARTICULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mgSource →
- Route: INTRABURSAL; Dosage form: INJECTION; Potency: ADJ PHSource →
- Route: INTRALESIONAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mgSource →
- Route: INTRAMUSCULAR; Dosage form: INJECTION; Potency: 200 mgSource →
- Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 80 mgSource →
- Route: INTRAMUSCULAR; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 279.27 mgSource →
- Route: INTRAMUSCULAR; Dosage form: INJECTION, SOLUTION; Potency: 0.34 %w/vSource →
- Route: INTRAMUSCULAR; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mgSource →
- Route: INTRASYNOVIAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mgSource →
- Route: INTRAVENOUS; Dosage form: INJECTION; Potency: 200 mgSource →
- Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 80 mgSource →
- Route: INTRAVENOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 279.27 mgSource →
- Route: INTRAVENOUS; Dosage form: INJECTION, SOLUTION; Maximum daily exposure: 43 mgSource →
- Route: INTRAVITREAL; Dosage form: INJECTION; Potency: 1.33 %w/vSource →
- Route: INTRAVITREAL; Dosage form: INJECTION, SUSPENSION; Maximum daily exposure: 3 mgSource →
- Route: NASAL; Dosage form: SPRAY; Maximum daily exposure: 5 mgSource →
- Route: NASAL; Dosage form: SPRAY, METERED; Maximum daily exposure: 5 mgSource →
- Route: OPHTHALMIC; Dosage form: SOLUTION; Potency: 2.15 %w/vSource →
- Route: OPHTHALMIC; Dosage form: SOLUTION/ DROPS; Maximum daily exposure: 4 mgSource →
- Route: OPHTHALMIC; Dosage form: SUSPENSION; Potency: 0.48 %w/wSource →
- Route: OPHTHALMIC; Dosage form: SUSPENSION/ DROPS; Potency: 0.48 %w/wSource →
- Route: ORAL; Dosage form: CAPSULE; Potency: 500 mgSource →
- Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 120 mgSource →
- Route: ORAL; Dosage form: SUSPENSION; Maximum daily exposure: 200 mgSource →
- Route: ORAL; Dosage form: SYRUP; Maximum daily exposure: 131 mgSource →
- Route: ORAL; Dosage form: TABLET; Potency: 80 mgSource →
- Route: ORAL; Dosage form: TABLET, COATED; Potency: 0.22 mgSource →
- Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Potency: 16.24 mgSource →
- Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Potency: 70 mgSource →
- Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Potency: 105 mgSource →
- Route: SOFT TISSUE; Dosage form: INJECTION; Maximum daily exposure: 3 mgSource →
- Route: SUBCUTANEOUS; Dosage form: INJECTION; Potency: 0.38 %w/vSource →
- Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, FOR SOLUTION; Potency: 3.2 mgSource →
- Route: SUBCUTANEOUS; Dosage form: INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION; Potency: 3.43 mgSource →
- Route: SUBCUTANEOUS; Dosage form: INJECTION, SUSPENSION; Potency: 0.38 %w/vSource →
- Route: TOPICAL; Dosage form: CREAM; Maximum daily exposure: 29 mgSource →
- + 5 more entries not shown
USEPAcommercial use observedEPA CPDat observed this chemical in 15 composition records across product categories including Laboratory supplies, Personal care, Medical/dental.
- EPA CPDat observed this chemical in 15 composition records across product categories including Laboratory supplies, Personal care, Medical/dental.Source →
USFDAmarketed drug occurrenceFDA NDC lists this ingredient in 137 active drug products and 141 total products.
- FDA NDC lists this ingredient in 137 active drug products and 141 total products.Source →
USFDAlisted in openFDA substanceopenFDA substance registry classifies this ingredient as chemical.
- openFDA substance registry classifies this ingredient as chemical.Source →
Evidence
No graded sources yet for Sodium phosphate, dibasic, heptahydrate. We publish evidence only once a source is linked and reviewed — this ingredient is in the catalog, but has not been assessed.
Suitability
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Good fit
Where it appears
Prevalence of Sodium phosphate, dibasic, heptahydrate in our catalog (fda_ndc).
Products
141
Found in these products
- Anti transpirant mandarine verteUshuaia · HygieneMinor
- Nivea Man FRESH OCEAN 0% Aluminium (ACH) 48h Deo-Schutz AntibakteriellNivea · HygieneMinor
- Hand Cream Concentrated UnscentedNeutrogena · BodyLow
- JAPAN SPA Traditon mit Lotusblumen-ExtraktBODY&SOUL WELLNESS · BodylotionCritical
- Gel à raserLabell Men · ShavingCritical
- White Black Face MaskNacomï · FaceMinor
- Mascarilla hidratante nocturnaFarmatodo · FaceLow
- Anticavity Toothpaste, Watermelon FlavorHiSmile · HygieneHigh
